Neuroendocrine peptides, characterized by virtue of hypophysiotropic effects, have been established to be key regulators of anterior pituitary cell functions and growth and also to often have broad significance as regulators of the endocrine and central nervous systems. The goals of this project are directed towards the chemical and biological characterization of neuroendocrine peptides controlling corticotropic and somatotropic pituitary cells. This involves: 1) Purification of novel peptides and characterization of their precursors and genes including the corticotropin releasing factor (CRF) binding protein, peptides derived from the mammalian melanin concentrating hormone precursor and a hypothetical ACTH inhibiting factor. 2) Investigation of the in vivo (with Project V) and in vitro expression of selected neuroendocrine genes, initially CRF. 3) Study of neuroendocrine peptide receptors and the mechanisms of action of peptides such as growth hormone releasing factor (GRF), somatostatin and activin (inhibin BetaBeta dimer) as they regulate the function and proliferation of somatotropic cells. 4) Development of neuroendocrine peptide pharmacology of CRF and GRF in collaboration with Project II to facilitate fundamental studies as well as to provide agents of potential clinical significance.

Project Start
Project End
Budget Start
Budget End
Support Year
15
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Salk Institute for Biological Studies
Department
Type
DUNS #
005436803
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Spierling, Samantha R; Mattock, Maegan; Zorrilla, Eric P (2017) Modeling hypohedonia following repeated social defeat: Individual vulnerability and dopaminergic involvement. Physiol Behav 177:99-106
Pilbrow, Anna P; Lewis, Kathy A; Perrin, Marilyn H et al. (2016) Cardiac CRFR1 Expression Is Elevated in Human Heart Failure and Modulated by Genetic Variation and Alternative Splicing. Endocrinology 157:4865-4874
Zhang, Cheng; Kuo, Ching-Chang; Moghadam, Setareh H et al. (2016) Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease. Alzheimers Dement 12:527-37
Erchegyi, Judit; Wang, Lixin; Gulyas, Jozsef et al. (2016) Characterization of Multisubstituted Corticotropin Releasing Factor (CRF) Peptide Antagonists (Astressins). J Med Chem 59:854-66
Cui, Changhai; Noronha, Antonio; Warren, Kenneth R et al. (2015) Brain pathways to recovery from alcohol dependence. Alcohol 49:435-52
Perrin, Marilyn H; Tan, Laura A; Vaughan, Joan M et al. (2015) Characterization of a Pachymedusa dacnicolor-Sauvagine analog as a new high-affinity radioligand for corticotropin-releasing factor receptor studies. J Pharmacol Exp Ther 353:307-17
Zhang, Cheng; Kuo, Ching-Chang; Moghadam, Setareh H et al. (2015) Corticotropin-Releasing Factor Receptor-1 Antagonism Reduces Oxidative Damage in an Alzheimer’s Disease Transgenic Mouse Model. J Alzheimers Dis 45:639-50
van der Meulen, Talitha; Huising, Mark O (2015) Role of transcription factors in the transdifferentiation of pancreatic islet cells. J Mol Endocrinol 54:R103-17
Radley, Jason J; Sawchenko, Paul E (2015) Evidence for involvement of a limbic paraventricular hypothalamic inhibitory network in hypothalamic-pituitary-adrenal axis adaptations to repeated stress. J Comp Neurol 523:2769-87
van der Meulen, Talitha; Donaldson, Cynthia J; Cáceres, Elena et al. (2015) Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat Med 21:769-76

Showing the most recent 10 out of 382 publications